The entity boundary
Full thymosin beta-4 and a marketed TB-500 fragment may differ in sequence, formulation, pharmacology, and evidence. Every inference on this site keeps that boundary visible.
What the located studies show
Full thymosin beta-4 has early human safety and route-specific clinical research, plus broader preclinical wound, cardiac, and neurological work. Direct fragment-specific human evidence for the marketed recovery use case remains unvalidated.
The entity mismatch comes before every outcome claim
The strongest located human studies concern full-length synthetic thymosin beta-4. FDA's inspected record discusses the marketed TB-500 LKKTETQ fragment separately and reports no identified human exposure data for that fragment. A shared commercial name or biological relationship does not make the materials interchangeable.
Sequence, molecular form, formulation, route, and exposure can change pharmacology. A vendor label also does not prove which sequence is present. The evidence review therefore names full-length thymosin beta-4 every time it describes those human studies instead of shortening the study material to TB-500.
What the full-length human studies can answer
The early intravenous study can support narrow observations about the defined full-length material, route, participants, and follow-up it reported. It cannot establish fragment-specific efficacy, long-term safety, musculoskeletal recovery, or a protocol for a research-vendor vial.
The ophthalmic phase 2 study tested a different route and formulation. Its two primary endpoints did not show significant differences, even though selected secondary outcomes differed. Primary and secondary outcomes must remain labeled because a secondary signal does not rewrite the prespecified primary result.
What evidence is still needed for TB-500
Fragment-specific human pharmacology, exposure, safety, dose-ranging, and efficacy studies were not identified in the inspected packet. Without that entity-matched foundation, claims about healing speed, injury recovery, dosing, preparation, or monitoring remain unsupported.
What this evidence review covers
Separate TB-500 fragment evidence from full-length thymosin beta-4 research.
- Entity map: full-length Tβ4 versus LKKTETQ fragment
- Full-length IV phase 1 safety study
- Full-length ophthalmic phase 2 study and failed primary endpoints
- Preclinical full-length repair literature as indirect evidence only
- FDA fragment-specific evidence gap
- Unsupported healing-speed and timeline claims
Source-backed findings
Each claim below is tied to the evidence class that can support it. Commercial listing data and clinical evidence remain separate.
direct human evidence for different entity
The 2010 randomized study tested full-length synthetic thymosin beta-4 intravenously in healthy volunteers.
direct human evidence for different entity/route
The ophthalmic phase 2 full-length Tβ4 study did not show significant differences on its two primary endpoints, though selected secondary outcomes differed.
fragment-specific regulatory evidence
FDA reports no identified human exposure data for the TB-500 LKKTETQ fragment and lacks enough information to know whether it would cause harm.
| Evidence class | What the source supports |
|---|---|
| direct human evidence for different entity | The 2010 randomized study tested full-length synthetic thymosin beta-4 intravenously in healthy volunteers. |
| direct human evidence for different entity/route | The ophthalmic phase 2 full-length Tβ4 study did not show significant differences on its two primary endpoints, though selected secondary outcomes differed. |
| fragment-specific regulatory evidence | FDA reports no identified human exposure data for the TB-500 LKKTETQ fragment and lacks enough information to know whether it would cause harm. |
Source-by-source evidence notes
These notes state what each inspected source can support and the boundary that should not be crossed when interpreting it.
Intravenous full-length thymosin beta-4 in healthy volunteers
Evidence class: primary randomized phase 1 entity mismatch. What it supports: Short-term tolerability and pharmacokinetics of characterized full-length thymosin beta-4 in healthy volunteers.
What it does not establish: TB-500 fragment identity, TB-500 safety, injury healing, retail-product quality, or a TB-500 dose.
Full-length thymosin beta-4 ophthalmic solution phase 2 trial
Evidence class: primary randomized phase 2 entity and route mismatch. What it supports: 72-person ophthalmic full-length Tβ4 study; primary endpoints were not significant; selected secondary endpoints differed.
What it does not establish: TB-500 fragment efficacy, systemic administration, injury protocols, or retail-vial safety.
FDA bulk substances that may present significant safety risks
Evidence class: primary regulatory. What it supports: FDA's BPC-157, injectable GHK-Cu, and TB-500 fragment safety/characterization statements; no identified human TB-500 fragment exposure data.
What it does not establish: A diagnosis, individual risk estimate, or claim that topical GHK-Cu and injectable GHK-Cu share one risk profile.
Questions this page answers
Are TB-500 and thymosin beta-4 interchangeable?
No. The page must keep fragment and full-length evidence in separate columns.
Did phase 2 prove TB-500 heals tissue?
No. The cited phase 2 study was an ophthalmic full-length Tβ4 trial, and its primary endpoints were not significant.
Is '61% faster wound healing' supported?
Not by the fragment-specific human packet; hold the claim unless a direct, entity-matched primary source is inspected.
What remains unresolved
- No identified human TB-500 fragment exposure data in FDA's inspected source.
- No entity-matched efficacy trial.
- Retail labels may not prove peptide sequence.
- Do not summarize full-length studies under a TB-500 heading without an entity-mismatch banner.